Clinical Trial

Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-01-29; most recent amendment 2025-03-18.
Status change: Not Yet Recruiting → Recruiting 2024-03-23
Trial Details
NCT Number NCT06231381
Lead Sponsor Shanghai Huaota Biopharmaceutical Co., Ltd.
Conditions Generalized Pustular Psoriasis (GPP)
Enrollment 33 participants
Start Date 2024-02-29
Primary Completion 2025-02-13 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-19